Communiqués Raspberry Pi Holdings plc

Actions

RPI

GB00BS3DYQ52

Matériels et logiciels intégrés

Marché Fermé - London S.E. 17:35:10 14/08/2026			Varia. 5j.	Varia. 1 janv.
666,50 ^GBX	-1,55%		-4,38%	+122,02%

14/08	PALMARÈS : Michael Page progresse grâce à UBS ; les valeurs logicielles en hausse	AN
12/08	Raspberry Pi Holdings plc : Berenberg Bank n'est plus positif	ZM

Communiqués

01/07	Raspberry Pi : Secure Raspberry Pi Connect at scale	PU
21/04	Raspberry Pi : Proxy Form	PU
21/04	Raspberry Pi : Notice of Annual General Meeting 2026	PU
08/12	Sustainable solutions: Our environmental, social, and governance metrics	PU
01/10/25	Raspberry Pi : $5–$10 price increases for some 4GB and 8GB products	PU
05/09/25	Raspberry Pi : 1TB Raspberry Pi SSD on sale now for $70	PU
04/09/25	New from Raspberry Pi Press: Unplugged Tots	PU
01/09/25	Raspberry Pi : Supersense SenS2 dementia aid	PU
29/08/25	Raspberry Pi : in the stratosphere	PU
28/08/25	Raspberry Pi : Play a new version of DOOM on SNES with the help of RP2350	PU
22/08/25	Raspberry Pi : Tommy-B-003 robot	PU
20/08/25	Raspberry Pi : Charles Babbage’s Analytical Engine \| The Computers that Made the World	PU
18/08/25	Raspberry Pi : A new 5″ variant of Raspberry Pi Touch Display 2	PU
14/08/25	Trimming the FAT: Flash Raspberry Pi OS images faster	PU
11/08/25	Raspberry Pi : Happy Maker Monday — show us your Raspberry Pi builds!	PU
08/08/25	Navigating the EU’s new Radio Equipment Directive: how Raspberry Pi provides an industrial advantage	PU
20/05/25	Raspberry Pi : Conquer the command line, 3rd edition — out now!	PU
17/04/25	Raspberry Pi : Notice of Availability	PU
17/04/25	Raspberry Pi : Proxy Form	PU
17/04/25	Raspberry Pi : Notice of Annual General Meeting 2025	PU
02/04/25	Raspberry Pi : Final results 2024 Document	PU
02/04/25	Raspberry Pi : Final results 2024 Presentation	PU
17/03/25	RP2350 now available to buy: a high-performance, secure microcontroller for your next project	PU
25/02/25	NGM Bio Announces First Participant Dosed in EMERALD Phase 2 Clinical Study of NGM120 for the Treatment of Hyperemesis Gravidarum in Pregnant Patients	AQ
18/07/24	NGM Bio Announces $122 Million Series a Financing to Initiate Registrational Trial in Primary Sclerosing Cholangitis and Fund Phase 2 Trial in Hyperemesis Gravidarum	AQ